CapiThera

CapiThera is a specialty pharmaceutical company based in London, UK, focused on the development and commercialization of novel medicines for severe headache disorders. A spin-off of the Swiss company Curatis AG, CapiThera specializes in repurposing established compounds for high unmet needs in neurology. The company's lead candidate, CAM-01 (picotamide), is a dual thromboxane A2 synthase inhibitor and thromboxane receptor antagonist currently in Phase 2 development for the prevention of migraine with aura. Its second program, C-MOH-01, is an oral noradrenergic and specific serotonergic inhibitor being advanced for the treatment and prevention of medication overuse headache (MOH). CapiThera leverages strategic partnerships and existing clinical data to accelerate the delivery of effective therapies to patients suffering from chronic and secondary headache conditions.